Review Article
Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
Table 3
Characteristics of certain HDACIs tested in CTCL.
| | | | HDAC class specificity | Potency | Route of administration | Clinical Status | Structure |
| | | Vorinostat | I, II, IV | nM | Oral | FDA approved (2006) |  | | Hydroxamate | Belinostat
(PXD101) | I, II, IV | nM | Oral/intravenous | Phase I, II |  | | | Panobinostat
(LBH589) | I, II, IV | nM | Oral | Phase II, III |  |
| | Benzamide | Entinostat
(MS-275) | I | M | Oral | Phase II |  |
| | Cyclic tetrapeptide | Depsipeptide
(FK228, romidepsin) | I, II, IV | nM | Intravenous | FDA approved (2009) |  |
|
|
